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Abstract
ABCB1 P-glycoprotein (P-gp) is an ATP-dependent efflux pump with broad
substrate specificity associated with cellular drug resistance. Homologous to role
in mammalian biology, P-glycoproteins of bacterial and fungal pathogens mediate
the emergence of multidrug resistance phenotypes, with widespread clinical/
socioeconomic implications. This work aims to characterize P-gp homologues in
certain WHO-prioritized infectious agents, namely (1) bacteria: Acinetobacter
baumannii and Staphylococcus aureus and (2) fungi: Aspergillus fumigatus, Candida
albicans, and Cryptococcus neoformans. PSI-BLAST searches against the genome
of each of these organisms confirmed the presence of P-gp homologues. Each
homologue was aligned against five known P-gp structures, for structural model-
ing. FDA-approved antibiotics used in the current line of therapy were retrieved
from PubChem, and potential antibiotics were identified based on similarity and
repurposing of the existing drugs. The most tenable target-ligand conformations
from docking studies of the respective modeled P-gp structures and the antibiotic
ligands were assessed for interacting residues within 4.5 Å of the ligand, probable
binding pockets and relative efficacies of the new drugs. Our studies could lay
the foundation for the development of effective synergistic or new therapies
against these pathogens.
Keywords: P-glycoprotein, priority pathogen list, nosocomial infection, multidrug
resistance, homology modeling, receptor-ligand docking, differential ligand
affinity, synergistic effects
1. Introduction
1.1 Multidrug resistance (MDR)
Bacterial evolution tends to respond to the selection constraint of reckless anti-
biotic use, which has led to the emergence of drug-resistant strains mediated by
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varied defense mechanisms. The main mechanisms whereby infectious agents
develop resistance to antimicrobial chemotherapy include enzymatic inactivation,
modification of the drug target(s), and reduction of intracellular drug concentra-
tion by changes in membrane permeability or by the overexpression of efflux
pumps [1]. Multidrug resistance efflux pumps are recognized as an important
component of resistance in both Gram-positive and Gram-negative bacteria [2].
Some bacterial efflux pumps may be selective for one substrate or transport antibi-
otics of different classes, conferring a multidrug resistance phenotype. With respect
to efflux pumps, they provide a self-defense mechanism whereby antibiotics are
extruded from the cell interior to the external environment. This results in sublethal
drug concentrations at the active site that in turn may predispose the organism to
the development of high-level target-based resistance [3]. Therefore, efflux pumps
are viable antibacterial targets and the development of potent efflux pump inhibi-
tors is a promising and valid strategy to rejuvenate the activity of antibiotics that are
no longer effective against bacterial pathogens. The world is searching for new tools
to combat multidrug resistance.
1.2 P-glycoprotein (P-gp)
ATP-binding cassette (ABC) transporters are found in all phyla and constitute one
of the largest protein superfamilies. ABC transporters such as ABCB1 (P-glycoprotein/
P-gp), ABCG2, and ABCC1 are well known for their association with multidrug
resistance, effluxing structurally diverse compounds, powered by the hydrolysis of
ATP [4]. P-gp also plays an important role in the pharmacokinetics of many drugs,
altering their absorption, distribution, and excretion. P-gp has been extensively
studied since 1976, when it was identified as the multidrug efflux pump in Chinese
hamster ovary cells that had been selected for resistance to colchicine [3].
In eukaryotes, it takes the form of a single polypeptide chain consisting of two
transmembrane domains (TMDs) that are usually arranged into six
transmembrane-spanning α-helices that form the pathway through which substrate
crosses the membrane. These domains also form the substrate-binding site (or sites)
which contribute to transport specificity. The two nucleotide-binding domains
(NBDs) couple the energy of ATP catalysis to transport [5]. In some prokaryotes,
however, the P-gp structure comprises a monomeric assembly, namely, a single
TMD and a single NTD. The various domains can comprise one, two, or four
polypeptide chains, encoded by the same or different genes, which assemble into
monomers, homo- or heterodimers, or tetramers.
Prokaryotes harbor both importers for nutrient uptake (including amino acids,
sugars, and metal ions) and exporters (drugs, toxins, polysaccharides, lipids, and
proteins), whereas eukaryotes harbor only exporters [6]. It is believed that this
transporter functions through an alternate access mechanism involving two differ-
ent conformations. Drug binding occurs to the inward-facing from the cytoplasm or
the inner leaflet of the bilayer. After binding two molecules of MgATP, the
nucleotide-binding domains (NBDs) dimerize and switch the transmembrane
domain (TMDs) from the inward- to the outward-facing conformation, followed by
the release of the drug to the extracellular milieu. ATP hydrolysis, ADP/Pi release,
and NBD dissociation reset the transporter to the inward-facing conformation.
The switch from inward to outward form certainly requires a highly flexible
structure [4, 7, 8].
Substrate “promiscuity” or polyspecificity is a well-known characteristic of P-gp
and the subject of much research. Attempts have been made to understand the
ability of P-gp to recognize various chemically and structurally diverse substrates
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through biochemical investigations and structural studies. Despite all these studies,
the molecular basis of this unusual property still remains poorly understood and is a
matter of intense debate [9].
2. Prioritizing pathogenic agents
Opportunistic pathogens with a response profile of drug resistance to antibiotic
treatment are good candidates for study. The organisms chosen here included
bacteria and fungi identified by theWHO as priority pathogens [10] as well as other
nosocomial pathogens that pose an elevated threat level due to acquisition of MDR
over the recent years. Nosocomial pathogens are subject to the evolutionary pres-
sure exerted by constant exposure to antibiotics in hospitals that could accelerate
the emergence of pathogenicity-related mutations.
2.1 Acinetobacter baumannii
Multidrug-resistant Acinetobacter baumannii strains are opportunistic bacterial
pathogens primarily associated with nosocomial infections worldwide [11]. Due to
the remarkable ability of A. baumannii to gain resistance to antibiotics, this bacte-
rium is now considered to be a “superbug.” Acinetobacter baumannii strains resis-
tant to all clinically relevant antibiotics known have also been isolated. Although
MDR A. baumannii (MDR-Ab) continues to disseminate globally, very little is
known about its pathogenesis mechanisms. Once detected within specific areas of
the hospital, various levels of intervention have been attempted to reduce the
incidence and prevalence of infection due to MDR-Ab [12].
Acinetobacter baumannii and its close relatives belonging to genomic species 3
(Acinetobacter pittii) and 13TU (Acinetobacter nosocomialis) are important nosoco-
mial pathogens, often associated with epidemic outbreaks of infection, that are only
rarely found outside of a clinical setting. These organisms are frequently pandrug-
resistant and are capable of causing substantial morbidity and mortality in patients
with severe underlying disease, both in the hospital and in the community [13].
Several epidemic clonal lineages of A. baumannii have disseminated worldwide and
seem to have a selective advantage over non-epidemic strains. Physicians are also
facing challenging therapeutic quandaries when treating patients infected with
MDR-Ab, because the increasing prevalence of resistance continues to restrict their
treatment options [14].
Urban et al. [12] gave us a look into the MDR in Acinetobacter baumannii,
discussing its medical relevance and treatment options. They sought to control infec-
tion due to MDR-Ab by identifying isolates as clonally related, leading to enhanced
infection-control measures, including cohorting, surveillance, contact precaution,
initial therapy with ampicillin/sulbactam and local polymyxin B, and, more recently,
therapy with synergistic antibiotic combinations. Gupta et al. [15] demonstrated the
existence of MDR-Ab and its significance. Park et al. [16] determined the complete
genome sequence of A. baumannii strain 1656-2 to study biofilm formation. This
strain is significant to the project due to its use in target selection.
2.2 Staphylococcus aureus
Staphylococcus aureus is a major human pathogen that causes a wide range of
clinical infections. Approximately 30% of the human population is colonized with
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S. aureus; however, it is a leading cause of bacteremia and infective endocarditis as
well as osteoarticular, skin and soft tissue, pleuropulmonary, and device-related
infections [17]. The WHO has categorized Staphylococcus aureus as a high-priority
pathogen that possesses MDR, as a consequence of its acquisition of methicillin and
vancomycin resistance.
Hiramatsu et al. [18] described the genetic basis for the remarkable ability of
S. aureus to acquire multi-antibiotic resistance and proposed a novel paradigm for
future chemotherapy against the multiresistant pathogens. The evolution of Staph-
ylococcus or for that matter any bacterium does not halt. Lemaire et al. [19] exam-
ined the effect of P-gp on the modulation of the intracellular accumulation and
activity of daptomycin towards phagocytosed Staphylococcus aureus in human THP-
1 macrophages, in comparison with MDCK epithelial cells. Handzlik et al. [2]
delineated recent achievements in the search for new chemical compounds able to
inhibit multidrug resistance mechanisms in Gram-positive pathogens.
2.3 Aspergillus fumigatus
Aspergillus fumigatus is a saprophytic fungus that plays an essential role in
recycling environmental carbon and nitrogen. Its natural ecological niche is the soil,
wherein it survives and grows on organic debris. Aspergillus fumigatus is of the more
prevalent opportunistic pathogens involved in human aspergillosis in which, though
a minor disease, because of the increase in the number of immunosuppressed patients
and the degree of severity of modern immunosuppressive therapies, the situation has
changed dramatically in recent years. The diversity of patients and risk factors com-
plicates diagnostic and therapeutic decision-making [20]. Invasive procedures are
often precluded by host status; noninvasive diagnostic tests vary in their sensitivity
and specificity. The ability of Aspergillus species to withstand antifungal treatment
may be due in part to the presence of the MDR mechanism of drug efflux.
Latge [20] reviewed taxonomy of aspergillosis, its symptoms, diagnosis, viru-
lence factors, defense mechanisms, epidemiology, and treatment. Little is known of
the cellular and humoral defense mechanisms which are essential for the killing of
A. fumigatus conidia and hyphae in the immunocompetent host. Tobin et al. [21]
identified genes encoding proteins of the ATP-binding cassette superfamily in
Aspergillus fumigatus and Aspergillus flavus. In A. fumigatus, two genes (AfuMDR1
and AfuMDR2) encoding proteins of the ATP-binding cassette superfamily were
identified, which are the probable homologue of human P-gp.
2.4 Candida albicans
Candida species have emerged among the top three causes of microbial nosoco-
mial infectious diseases in humans, resulting in 46–75% mortality. The incidence of
candidiasis has increased sharply over the past few decades, primarily due to hos-
pital interventions such as cancer chemotherapy, surgery, organ/bone marrow
transplantation, and indwelling devices [22]. Of note, recently, the incidences of
albicans and non-albicans species of Candida acquiring resistance to antifungals
(particularly to azoles) have increased considerably which poses problems towards
its successful chemotherapy [23]. Drug transporters, such as the ATP-binding cas-
sette transporters encoded by CDR1 and CDR2 (Candida drug resistance), and a
major facilitator superfamily (MFS) transporter encoded byMDR1, play key roles in
azole resistance as deduced by their high level of expression in the majority of azole-
resistant clinical Candida albicans isolates [22].
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Schubert et al. [24] stated that constitutive overexpression of the Mdr1 efflux
pump was an important mechanism of acquired drug resistance C. albicans. The
Mdr1 efflux pump is a P-gp homologue and is hence significant to this project. Sun
et al. [22] highlighted an extensive upregulation of MDR1 as well as polyamine
transporter genes in a fluconazole-resistant strain, going further to correlate the
presence of MDR1 in C. albicans and its role in fluconazole resistance.
2.5 Cryptococcus neoformans
Cryptococcus neoformans is an encapsulated fungal pathogen that is remarkable for
its tendency to cause meningoencephalitis, especially in patients with AIDS. While
the disease is less common in children than adults, it remains an important cause of
morbidity and mortality among HIV-infected children without access to anti-
retroviral therapy [25]. Cryptococcus neoformans is a basidiomycetous yeast ubiquitous
in the environment and a model for fungal pathogenesis. CneMDR1, a gene encoding
a protein related to several eukaryotic multidrug resistance proteins, was identified,
cloned, and characterized from a clinical isolate of Cryptococcus neoformans [26].
Kao and Goldman [25] reviewed recent insights into both the biology and treat-
ment of cryptococcosis with a special emphasis on the pediatric literature.
Thornewell et al. [26] characterized the CneMDR1 gene. Protein structure predic-
tions suggested the presence of two putative 6-transmembrane (TM) domains as
well as two ATP-binding domains, structural characteristics typical of ATP-binding
cassette (ABC) proteins, including P-glycoprotein.
3. Sequence and structure analyses
3.1 Bacterial P-glycoprotein efflux pumps
Bacterial P-glycoproteins were identified based on homology to the mammalian
P-gp in the following manner. The position-specific iterated BLAST (PSI-BLAST)
was performed against a search set of nonredundant protein sequences in the
organism of interest, using hP-GP as the query (hP-gp; UniProt P08183). Through a
PSI-BLAST search, a large set of related proteins are compiled. It is used to identify
distant evolutionary relationships between protein sequences. The algorithm
parameters were set with an E-value of 0.001, and the scoring matrix BLOSUM62
was used. This step was performed on all four organisms of interest (Aspergillus
fumigatus, Acinetobacter baumannii, Staphylococcus aureus, Candida albicans, Cryp-
tococcus neoformans). Hundreds of hits were obtained for P-glycoprotein, and these
results were prioritized according to predetermined parameters such as medical
relevance, annotation status, and the presence of conserved regions. The results
were analyzed, and the P-glycoprotein sequence of each organism was finalized and
recorded as in Appendix A. The results were filtered for the organisms of interest
and shown in Table 1.
Hundreds of hits are obtained for P-glycoprotein, and these results were priori-
tized according to medical relevance and sequence identity. The significance of the
sequence identity is that, with a higher sequence identity, there is a higher similarity
between the query sequence and the aligned sequence. This project will focus on
nosocomial bacterial and fungal strains. The chosen sequences would have con-
served regions determined through multiple sequence alignment with the ClustalX2
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software, the most widely used multiple alignment programs. The guide trees in
Clustal were calculated using the neighbor-joining (NJ) method [27].
3.2 Homology modeling
The target sequences and the suitable templates were chosen and aligned using
ClustalX2. Multiple sequence alignment was performed between the targets and the
templates so that the homology and evolutionary relationship between the
sequences of the biological data set can be inferred [27]. This information was
considered in the structure validation. The templates chosen are:
• 4M1M—Mus musculus
• 2HYD—Staphylococcus aureus
• 3B5Z—Salmonella enterica
• 3WME—Cyanidioschyzon merolae
• 4F4C—Caenorhabditis elegans
The p-glycoprotein sequences would be used as target sequences for structure
modeling with SWISS-MODEL [28]. SWISS-MODEL is an open-source, structural
bioinformatics tool used for the automated comparative modeling of three-
dimensional protein structures. Several P-glycoprotein structures were modeled for
each organism, using multiple templates. The templates having high sequence sim-
ilarity with the target sequences were given preference. The objective of homology
modeling is to identify the best template and build the PDB model of the macro-
molecule to be used in docking. Modeling of the predetermined templates was
accepted if they resulted in high modeling (GMQE) scores. Each modeled structure
was saved as a PDB file. The results are summarized in Table 3.
The validity was checked using the Ramachandran plot with tools such as
Procheck. The structures were refined using energy minimization protocols, and
the least energetic structure corresponding to each efflux pump protein was chosen
for docking studies.
In summary, the FASTA sequences of the BLAST results were obtained and fed
into the SWISS-MODEL to build homology models with the above set of templates.
The SWISS-MODEL provided us with the top 100 templates that can be used to
generate a homology model. To generate the best possible homology model, the
templates were aligned with the target organisms using the multiple alignment tool
Clustalx2, and a phylogenetic analysis is subsequently conducted.
Organism Max score Total score Query cover (%) Ident (%) Length
Aspergillus fumigatus 966 1389 97.00 42.00 1349
Acinetobacter baumannii 256 498 82.00 32.00 555
Staphylococcus aureus 268 504 58.00 34.00 578
Candida albicans 183 352 88.00 23.00 1606
Cryptococcus neoformans 931 931 97.00 42.00 1408
Table 1.
Summary of BLAST results.
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From Table 2, it could be inferred that in the cases of Aspergillus fumigatus and
Cryptococcus neoformans, 4m1m was the most phylogenetically favored templates.
Candida albicans and Staphylococcus aureus are phylogenetically favored to the 2hyd
template, and Acinetobacter baumannii is phylogenetically closer to 3b5z.
The validity of the homology models was further checked with Phi-Psi graphs and
Chi1-Chi2 plots for each residue type. The template comparison is done based on:
• Taxonomy of the target organism with respect to the templates
• Distance analysis
Subsequent to the Ramachandran plot validation, from Table 3, we can infer
that 4m1m is preferred in Aspergillus fumigatus, Aspergillus nidulans, Acinetobacter
Templates Phylogenetic distance
A. fumigatus A. baumannii C. albicans S. aureus C. neoformans
3wme 0.635 0.701 0.844 0.707 0.632
4f4c 0.641 0.703 0.831 0.716 0.637
4m1m 0.584 0.707 0.842 0.711 0.577
2hyd 0.728 0.623 0.81 0.602 0.711
3b5z 0.678 0.592 0.827 0.661 0.694
Bold values indicate the phylogenetically nearest structure.
Table 2.
Phylogenetic distance between templates and the target sequence of each organism.
Total residues Query cover (%) Sequence identity
Organism: Aspergillus fumigatus
3wme.1.a 565 0.43 37.8
4f4c.1.a 1241 0.91 37.48
4m1m.2.a 1251 0.91 42.15
Organism: Acinetobacter baumannii
3wme.1.a 550 0.99 30.29
4f4c.1.a 537 0.99 28.88
4m1m.2.a 545 0.97 32.22
Organism: Candida albicans
4f4c.1.a 912 0.52 17
4m1m.2.a 1272 0.7 18.83
Organism: Staphylococcus aureus
3wme 575 0.98 29.75
Organism: Cryptococcus neoformans
3wme.1.a 608 0.41 37.89
4f4c.1.a 1259 0.88 37.74
4m1m.1.a 582 0.41 38.5
Bold values indicate optimal parameter values for each organism.
Table 3.
Results of template parameter comparison—homology results.
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Antibiotic PubChemID SMILES format
Amikacin 37768 C1C(C(C(C(C1NC(]O)C(CCN)O)OC2C(C(C(C(O2)CO)O)N)O)
O)OC3C(C(C(C(O3)CN)O)O)O)N
Colistin 5311054 CCC(C)CCCC(]O)NC(CCN)C(]O)NC(C(C)O)C(]O)NC(CCN)
C(]O)NC1CCNC(]O)C(NC(]O)C(NC(]O)C(NC(]O)C(NC
(]O)C(NC(]O)C(NC1]O)CCN)CC(C)C)CC(C)C)CCN)CCN)C
(C)O
Kanamycin 6032 C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)O)O)OC3C(C(C(C
(O3)CO)O)N)O)N
Netilmicin 90658113 CCNC1CC(C(C(C1OC2C(C(C(CO2)O)NC)(C)O)O)OC3C(CC]C
(O3)CN)N)N
Sulbactam 130313 CC1(C(N2C(S1(]O)]O)CC2]O)C(]O)O)C
Amphotericin B 5280965 CC1C]CC]CC]CC]CC]CC]CC]CC(CC2C(C(CC(O2)(CC
(CC(C(CCC(CC(CC(]O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(]
O)O)OC3C(C(C(C(O3)C)O)N)O
Anidulafungin 166548 CCCCCOC1]CC]C(C]C1)C2]CC]C(C]C2)C3]CC]C(C]
C3)C(]O)NC4CC(C(NC(]O)C5C(C(CN5C(]O)C(NC(]O)C
(NC(]O)C6CC(CN6C(]O)C(NC4]O)C(C)O)O)C(C(C7]CC]
C(C]C7)O)O)O)C(C)O)C)O)O)O
Isavuconazonium 6918606 CC(C1]NC(]CS1)C2]CC]C(C]C2)C#N)C(CN3C][N+](C]
N3)C(C)OC(]O)N(C)C4]C(C]CC]N4)COC(]O)CNC)(C5]
C(C]CC(]C5)F)F)O
Itraconazole 55283 CCC(C)N1C(]O)N(C]N1)C2]CC]C(C]C2)N3CCN(CC3)
C4]CC]C(C]C4)OC[C@H]5CO[C@](O5)(CN6C]NC]N6)
C7]C(C]C(C]C7)Cl)Cl
Micafungin 477468 CCCCCOC1]CC]C(C]C1)C2]CC(]NO2)C3]CC]C(C]C3)
C(]O)NC4CC(C(NC(]O)C5C(C(CN5C(]O)C(NC(]O)C(NC
(]O)C6CC(CN6C(]O)C(NC4]O)C(C)O)O)C(C(C7]CC(]C
(C]C7)O)OS(]O)(]O)O)O)O)C(CC(]O)N)O)C)O)O)O
Porfimer 57166 CC1]C(C2]CC3]NC(]CC4]NC(]CC5]C(C(]C(N5)C]
C1N2)C(C)OC(C)C6]C(C7]CC8]C(C(]C(N8)C]C9C(]C(C
(]N9)C]C1C(]C(C(]N1)C]C6N7)C)CCC(]O)O)CCC(]O)
O)C)C)C(C)O)C)C)C(]C4CCC(]O)O)C)C(]C3C)CCC(]O)O)
C(C)O
Voriconazole 71616 CC(C1]NC]NC]C1F)C(CN2C]NC]N2)(C3]C(C]C(C]C3)
F)F)O
Fluconazole 3365 C1]CC(]C(C]C1F)F)C(CN2C]NC]N2)(CN3C]NC]N3)O
Clotrimazole 2812 C1]CC]C(C]C1)C(C2]CC]CC]C2)(C3]CC]CC]C3Cl)
N4C]CN]C4
Nystop 11953884 CC1C]CC]CCCC]CC]CC]CC]CC(CC(C(C(CC(]O)CC(C
(CCC(CC(CC(CC(]O)OC(C(C1O)C)C)O)O)O)O)O)O)C(]O)O)
O)OC2C(C(C(C(O2)C)O)N)O
Clindamycin 29029 CCCC1CC(N(C1)C)C(]O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl
Finafloxacin 11567473 C1CC1N2C]C(C(]O)C3]CC(]C(C(]C32)C#N)N4CC5C(C4)
OCCN5)F)C(]O)O
Vancomycin 14969 CC1C(C(CC(O1)OC2C(C(C(OC2OC3]C4C]C5C]C3OC6]C
(C]C(C]C6)C(C(C(]O)NC(C(]O)NC5C(]O)NC7C8]CC(]
C(C]C8)O)C9]C(C]C(C]C9C(NC(]O)C(C(C1]CC(]C(O4)
C]C1)Cl)O)NC7]O)C(]O)O)O)O)CC(]O)N)NC(]O)C(CC
(C)C)NC)O)Cl)CO)O)O)(C)N)O
Table 4.
List of known FDA approved antibiotics.
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baumannii, and Candida albicans; 4m1m is the best template. In Cryptococcus
neoformans, 4f4c is preferred, and 3wme is preferred in Staphylococcus aureus.
4. Antibiotics of interest
A set of antibiotics were identified for the purposes of investigation and
included known FDA-approved antibiotics (Table 4) against each of the target
organisms as well as promising antibiotics that ranged from repurposed to investi-
gational (Table 5).
For each structure, we surveyed the literature to determine the known antibi-
otics that are effective against it and against which the pathogenic strain might have
Compound PubChemID SMILES format
Levofloxacin 149096 CC1COC2]C3N1C]C(C(]O)C3]CC(]C2N4CCN(CC4)C)F)C(]
O)O
Moxifloxacin 152946 COC1]C2C(]CC(]C1N3CC4CCCNC4C3)F)C(]O)C(]
CN2C5CC5)C(]O)O
Tigecycline 54686904 CC(C)(C)NCC(]O)NC1]C(C2]C(CC3CC4C(C(]O)C(]C(C4(C
(]O)C3]C2O)O)O)C(]O)N)N(C)C)C(]C1)N(C)C)O
Trovafloxacin 62959 C1C2C(C2N)CN1C3]C(C]C4C(]O)C(]CN(C4]N3)C5]C(C]C
(C]C5)F)F)C(]O)O)F
Echinocandin 71723607 CC1CN2C(C1O)C(]O)NCC(CC(C(]O)NC(C(]O)N3CC(CC3C(]
O)NC(C(]O)NC(C2]O)C(CCNC(CO)CO)O)C(CC4]CC(]C(C]
C4)O)OC)O)O)C(C)O)NCC5CCC(CC5)C(]N)SC(]N)C6]CC]C
(C]C6)N7CCC(CC7)(C8CCCCC8)OC)O
Terbinafine 1549008 CC(C)(C)C#CC]CCN(C)CC1]CC]CC2]CC]CC]C21
VL-2397 77843968 CC(C)CC1C(]O)NC(C(]O)NC(C(]O)NC(C(]O)NC(C(]O)NC
(C(]O)N1)CC(]O)N)CCCN(C(]O)C)[O-])CCCN(C(]O)C)[O-])
CCCN(C(]O)C)[O-])CC2]CC]CC]C2.[Al+3]
Bithionol 2406 C1]C(C]C(C(]C1Cl)O)SC2]CC(]CC(]C2O)Cl)Cl)Cl
Carvacrol 10364 CC1]C(C]C(C]C1)C(C)C)O
VT-1129 91886002 C1]CC(]CC]C1C2]CN]C(C]C2)C(C(CN3C]NN]N3)(C4]C
(C]C(C]C4)F)F)O)(F)F)OC(F)(F)F
Aminocandin 16072305 CCCCCCCCOC1]CC]C(C]C1)C2]CC]C(C]C2)C(]O)NC3CC
(CNC(]O)C4C(C(CN4C(]O)C(NC(]O)C(NC(]O)C5CC(CN5C
(]O)C(NC3]O)C(C)O)O)C(CC6]CC]CC]C6)O)CO)C)O)
NCCN
Caspofungin 16119814 C1CC(C(C1)N)C(]O)O
E1210 16719049 C1]CC]NC(]C1)OCC2]CC]C(C]C2)CC3]NOC(]C3)C4]C
(N]CC]C4)N
Ceftobiprole 6918430 Nc1nc(ns1)\C(]N\O)\C(]O)N[C@H]2[C@H]3SCC(]C(N3C2]O)
C(]O)O)\C]C\4/CCN([C@@H]5CCNC5)C4]O
Brilacidin 25023695 C1CNCC1OC2]C(C]C(C]C2NC(]O)CCCCN]C(N)N)C(F)(F)F)
NC(]O)C3]CC(]NC]N3)C(]O)NC4]C(C(]CC(]C4)C(F)(F)
F)NC(]O)CCCCN]C(N)N)OC5CCNC5
Radezolid 11224409 CC(]O)NCC1CN(C(]O)O1)C2]CC(]C(C]C2)C3]CC]C(C]
C3)CNCC4]NNN]C4)F
Table 5.
List of repurposed and investigational antibiotics.
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developed resistance via efflux pump activity. A set of ligands is created for each
efflux pump, comprising of known and potential antibiotics. The PDB model of
each antibiotic is generated using MarvinView by converting the canonical SMILES.
This PDB model will act as the ligand during the docking process.
Open Babel is a file conversion software that provides a wide variety of options
[29]. We use it to convert the canonical SMILES of the ligand set into a .pdb file in
order to perform docking. However, we use this software again during visualization
to convert the docked complex from .pdb to .pdbqt format in order for it to be
recognized by RasMol.
5. Docking studies of pump-drug combinations
5.1 Docking of the bacterial efflux pumps with known and potential antibiotics
Computational docking is widely used for the study of protein-ligand interac-
tions and for drug discovery and development. The methods are fast enough to
allow virtual screening of ligand libraries containing tens of thousands of com-
pounds. Typically, the process starts with a target of known structure, such as a
crystallographic structure of an enzyme of medicinal interest. Docking is then used
to predict the bound conformation and binding free energy of small molecules to
the target. Single docking experiments are useful for exploring the function of the
target, and virtual screening, in which a large library of compounds are docked and
ranked, may be used to identify new inhibitors for drug development. With
AutoDock, it is possible to accomplish the following: basic docking of a drug mole-
cule with an anticancer target, a virtual screen of this target with a small ligand
library, docking with selective receptor flexibility, active site prediction, and
docking with explicit hydration.
The molecular docking was carried out using the AutoDock suite of tools [30].
The search algorithm used was the Lamarckian genetic algorithm (LGA), which
could handle ligands with more degrees of freedom than the simulated annealing
method used in earlier versions of AUTODOCK. LGA is the most efficient, reliable,
and successful search algorithm and mimics a heuristic Lamarckian evolution, a
controversial hypothesis proposed by Jean Batiste de Lamarck that phenotypic char-
acteristics acquired during an individual’s lifetime could become heritable traits. The
affinity maps were used to compute for each ligand-target pair. The docking param-
eters were set to 10 runs per receptor-ligand complex yielding 10 poses per each
docked complex. Based on the interaction energies, the pose with the smallest free
energy of binding was identified as the best pose of the drug and the target.
Each drug is docked with each subsequent target using AutoDock 4.2. The
results are analyzed to verify whether the pathogenic strain could develop resis-
tance to known antibiotics using efflux pump activity and if the novel antibiotics
could be effective against the development of such resistance.
5.2 Best pose analysis
The ligand pose with the least binding energy is defined as the best pose which
was validated by clustering at 2.0 Å r.m.s. The clusterings signify the extent of
difference between the various poses. Extremely similar poses will be clustered
together, increasing the validity of that respective pose. Thus the best pose is
selected based on the combination of the binding energy released and the cluster-
ings of the pose. The output contains the docked structure between the
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macromolecule and the best pose ligand. The output is a PDBQT file which is then
converted to PDB format using Open Babel. Tables 6 and 7 depict the best pose for
every organism in a hierarchy, in the case of both known and investigational drugs,
respectively.
5.3 Differential ligand binding affinity
The differential binding affinities of the repurposed ligands will be determined
using the conventionally used drugs as a baseline. The differential binding affinity
of a potential antibiotic with respect to a known antibiotic can be calculated by
subtracting the binding energy value generated by the known antibiotic from that
of the unknown antibiotic. A lower differential energy value is indicative of a more
stable complex.
ΔΔGpotential ¼ ΔGbind,potential  ΔGbind,known (1)
In the above formula, ΔΔGpotential is the differential binding affinity of the
potential ligand, and ΔGbind is the free energy released during docking. From
Table 8 it is evident that bithionol is the best investigational drug for the Aspergillus
Organism Known drug ΔG kcal/mol
Aspergillus fumigatus Amphotericin 6.99
Itraconazole 3.71
Anidulafungin 3.06
Micafungin 2.97
Voriconazole 2.6
Isavuconazonium 1.1
Porfimer 0.31
Candida albicans Amphotericin 7
Nystatin 6.22
Clotrimazole 5.43
Caspofungin 3.57
Acinetobacter baumannii Sulbactam 4.86
Kanamycin 4.11
Amikacin 3.46
Netilmicin 1.75
Colistin 4.54
Staphylococcus aureus Finafloxacin 5.9
Cephalexin 3.19
Vancomycin 3.18
Cryptococcus neoformans Amphotericin 6.7
Fluconazole 3.55
Voriconazole 2.3
Table 6.
Summary of the docking results of known antibiotics.
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fumigatus compared with other repurposed ligand used. From Table 9 we can infer
E1210 as a potential repurposed ligand for Candida albicans. Table 10 depicts the
differential binding abilities of repurposed ligand for Acinetobacter baumannii of
which moxifloxacin is the best investigational drug. In Tables 11 and 12, tigecycline
and bithionol were the most efficient potential antibiotics for the organisms
Staphylococcus aureus and Cryptococcus neoformans, respectively.
5.4 Identification of interacting residues in each docked complex
The best pose of each docked complex is viewed using RasMol and Pymol v.1.3.
All interacting residues within a radius of 4.5 Å of the ligand are restricted using
Organism Investigational drug ΔG kcal/mol
Aspergillus fumigatus Bithionol 5.9
Moxifloxacin 4.76
e1210 4.12
Terbinafine 3.76
Cresemba 0.45
Echinocandin 0.03
Candida albicans e1210 5.22
Moxifloxacin 4.76
Levofloxacin 4.66
Aminocandin 2.71
Bithionol 4.6
Acinetobacter baumannii Levofloxacin 6.34
Gepotidacin 5.58
Tigecycline 4.85
Ceftobiprole 4.72
Moxifloxacin 4.68
Trovafloxacin 4.03
Tigecycline 5.75
Staphylococcus aureus Gepotidacin 5.12
Moxifloxacin 4.92
Ceftobiprole 4.18
934628_27_0 3.89
Radezolid 3.63
Brilacidin 0.82
Cryptococcus neoformans Bithionol 4.98
e1210 4.89
Carvacrol 4.23
Moxifloxacin 4.04
vt-1129 3.85
Table 7.
Summary of the docking results of investigational drugs.
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Aspergillus fumigatus ΔΔGamphotericin ΔΔGitraconazole ΔΔGanidulafungin ΔΔGmicafungin ΔΔGvoriconazole ΔΔGisavuconazonium ΔΔGporfimer
Bithionol 1.09 2.19 2.84 2.93 3.3 4.8 5.59
Moxifloxacin 2.23 1.05 1.7 1.79 2.16 3.66 4.45
E1210 2.87 0.41 1.06 1.15 1.52 3.02 3.81
Terbinafine 3.23 0.05 0.7 0.79 1.16 2.66 3.45
Cresemba 6.54 3.26 2.61 2.52 2.15 0.65 0.14
Echinocandin 7.02 3.74 3.09 3 2.63 1.13 0.34
Bold values indicate that the differential free energy of binding of the potential antibiotic is negative (i.e., stronger binding).
Table 8.
Differential binding affinities of the repurposed ligands for Aspergillus fumigatus.
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Candida albicans ΔΔGamphotericin ΔΔGnystatin ΔΔGclotrimazole ΔΔGcaspofungin
E1210 1.78 1 0.21 1.65
Moxifloxacin 2.24 1.46 0.67 1.19
Levofloxacin 2.34 1.56 0.77 1.09
Bithionol 2.4 1.62 0.83 1.03
Aminocandin 4.29 3.51 2.72 0.86
Bold values indicate that the differential free energy of binding of the potential antibiotic is negative (i.e., stronger
binding).
Table 9.
Differential binding affinities of the repurposed ligands for Candida albicans.
Acinetobacter baumannii ΔΔGsulbactam ΔΔGkanamycin ΔΔGamikacin ΔΔGnetilmicin
Moxifloxacin 1.48 2.23 2.88 4.59
Tigecycline 0.01 0.74 1.39 3.1
Ceftobiprole 0.14 0.61 1.26 2.97
Levofloxacin 0.18 0.57 1.22 2.93
Bold values indicate that the differential free energy of binding of the potential antibiotic is negative (i.e., stronger
binding).
Table 10.
Differential binding affinities of the repurposed ligands for Acinetobacter baumannii.
Staphylococcus aureus ΔΔGfinafloxacin ΔΔGcephalexin ΔΔGvancomycin
Tigecycline 0.15 2.56 2.57
Gepotidacin 0.78 1.93 1.94
Moxifloxacin 0.98 1.73 1.74
Ceftobiprole 1.72 0.99 1
934628_27_0 2.01 0.7 0.71
Radezolid 2.27 0.44 0.45
Brilacidin 6.72 4.01 4
Bold values indicate that the differential free energy of binding of the potential antibiotic is negative (i.e., stronger
binding).
Table 11.
Differential binding affinities of the repurposed ligands for Staphylococcus aureus.
Cryptococcus neoformans ΔΔGamphotericin ΔΔGfluconazole ΔΔGvoriconazole
Bithionol 1.72 1.43 2.68
E1210 1.81 1.34 2.59
Carvocrol 2.47 0.68 1.93
Moxifloxacin 2.66 0.49 1.74
VT-1129 2.85 0.3 1.55
Bold values indicate that the differential free energy of binding of the potential antibiotic is negative (i.e., stronger
binding).
Table 12.
Differential binding affinities of the repurposed ligands for Cryptococcus neoformans.
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RasMol. By studying the PDB file constituting the restricting structure, we can
identify the atoms that are present within the interacting residues. These interacting
residues are then analyzed for recurrences, which are found to be the most active
Antibiotics Interacting residues
Amikacin Ala64, Ser67, Arg68, Arg75, Met103, Tyr104, Glu107, Thr110, Glu115
Colistin Ala87, Tyr90, Leu91, Ser94, Ser95
Kanamycin His290, Glu294, Leu295, Asp297, Leu298, Pro299
Netilmicin Asp277, Val278, Asn279, Glu280, Lys281
Sulbactam Ser160, Lys161, Arg164, Lys165, Met168, Gln283
Ceftobiprole Ile120, Asp123, Gly153, Val156, Arg157, Ser160, Met163, Leu268, Lys273, Thr276
Gepotidacin Gly153, Val156, Arg157, Ser160, Leu268, Lys273, Thr276, Asn279, Leu282, Gln283,
Leu286
Levofloxacin Val78, Tyr79, Ala80, Lys81, Leu82, Leu83, Arg84, Leu85, Tyr90, Asn93, Lys101,
Ser291, Val292, Glu294, Leu295, Leu296
Moxifloxacin Leu384, Ser385, Arg388, Met393, Tyr411, Gly412, Leu414, Arg465, Ala466, Lys469
Tigecycline Tyr79, Leu83, Tyr90, Ser95, Ile98, Met393, Asn395, Gln397, Val398, Val399, Phe401,
Tyr411, Arg465
Trovafloxacin Ile391, Ala392, Met393, Asn395, Phe401, Tyr411, Gly412, Leu414, Arg465, Ala466,
Lys469
Table 13.
Analysis of interacting residues for Acinetobacter baumannii.
Antibiotics Interacting residues
Amphotericin Thr221, Asn225, Phe756, Tyr759, Ser760, Gln953, Lys956, Ser957, Glu960, Ala963
Anidulafungin Trp762, Thr763, Leu764, Phe942, Gly1058, Thr1059, Phe1061, Ser1062, Asp1066,
Met1067, Gly1068, Lys1071, Asn1072
Isavuconazonium Asn392, Leu938, Gly941, Phe942, Arg944, Phe945, Gln1055, Ala1057, Gly1058,
Thr1059, Phe1061, Ser1062
Itraconazole Phe388, Gly391, Asn392, Leu938, Gly941, Phe942, Phe945, Gln1055, Gly1058,
Thr1059, Phe1061, Ser1062, Met1067
Micafungin Trp762, Leu938, Gly941, Phe942, Phe945, Tyr946, Ala949, Gln950, Gln953,
Gly1058, Phe1061, Gly1068, Lys1071, Asn1072
Porfimer Lys210, Glu215, Arg219, Asp223, Ala405, Ala408, Lys409, Ser412, Arg416
Voriconazole Ser760, Leu761, Trp762, Thr763, Leu764, Val765, Lys766, Gly1068, Lys1071,
Asn1072
Bithionol Phe348, Phe352, Tyr355, Ile385, Gln793, Gln796, Tyr800, Phe1052, Gln1055,
Ser1056, Thr1059
Cresemba The238, Phe242, Val393, Ala394, Gly397, Gln398, Phe400, Thr401
E1210 Glu186, Gln228, Arg954, Ser955, Ala958, Lys995, Gln996, Lys999, Ser1003
Echinocandin Thr218, Thr221, Gln580, Arg581, Val752, Gln755, Phe756, Lys758, Tyr759, Glu876,
Glu877, Lys956, Glu960, Ala963
Moxifloxacin Arg307, Tyr1113, Thr1115, Arg1116, Glu1118, Gln1119, Val1121, Gly1142, Cys1143,
Gly1144, Lys1145, Ser1146, Thr1147, Tyr1156
Terbinafine Gln755, Phe756, Glu757, Lys758, Tyr759, Arg875, Glu877
Table 14.
Analysis of interacting residues for Aspergillus fumigatus.
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interactive residues within the respective macromolecule. An analysis of the
interacting residues showed us that:
• (Leu268, Lys273, Thr276, Asn279) and (Gly153, Val156, Arg157, Ser160) are
some recurring residues in Acinetobacter baumannii (Table 13).
• (Phe942, Gly1058, Thr1059, Phe1061, Ser1062) and (Asn392, Leu938, Gly941)
are some recurring residues in Aspergillus fumigates (Table 14).
• (Phe1143, Thr1146, Phe1173, Asn1176, Tyr1177, Arg1179, Ile1180, Ile1317) and
(Gly978, His1357, Leu1358) are some recurring residues in Candida albicans
(Table 15).
Antibiotics Interacting residues
Amphotericin Phe1143, Thr1146, Leu1147, Phe1151, Val1152, Ser1170, Phe1173, Val1174, Asn1176,
Tyr1177, Arg1179, Ile1180, Ile1313, Glu1314, Ile1318, Tyr1319
Caspofungin Ser1104, Val1105, Leu1106, Arg1107, Ser1108, Phe1113, Ile1121, Phe1125, Asp1332
Clotrimazole Tyr1175, Phe1178, Arg1179, Phe1182, Val1183, Arg1187, Thr1254, Ser1257, Ser1258,
Phe1261, Phe1262
Nystatin Arg1002, Thr1005, Val1006, Pro1007, Trp1008, Asp1009, Ile1010, Phe1011, Asn1135,
Phe1143, Phe1173, Pro1323, Pro1327
Aminocandin Asp836, Val953, Asp954, Met1110, Asp1114, Tyr1354, Asp1359, Pro1360, Val1361,
Arg1380, Thr1381, Ala1383, Gly1384, Leu1390, Gln1422, Leu1573, Asp1574, Ser1575,
Gly1576
Bithionol Phe1143, Thr1146, Phe1173, Asn1176, Tyr1177, Arg1179, Ile1180, Ile1317, Glu1318,
Tyr1319
E1210 Arg992, Lys993, Thr994, Arg995, His996, Glu997, Gln998, Glu999, Glu1000, Ser1001,
Arg1002, Thr1116, Arg1120, Arg1124, Met1332, Lys1333
Levofloxacin Val953, Val975, Gly978, His1357, Leu1358, Asp1359, Pro1360
Moxifloxacin Tyr977, Gly978, Ser1111, Phe1112, Thr1115, Lys1333, Arg1355, Lys1356, His1357,
Leu1358
Table 15.
Analysis of interacting residues for Candida albicans.
Antibiotics Interacting residues
Amphotericin The280, Glu583, Pro584, Thr585, Leu586, Phe587, Gly641, Glu642, Leu646, Leu647,
Gly649, Lys652, His1020, Ser1023, Glu1024, Gly1027, Ala1028
Fluconazole Asp801, Ile802, Gln803, Ala804, Arg806, Ala807, Val810, Ala811, Gly812, Glu813,
Asp814, Lys815, Gln946, Lys949
Voriconazole SER818, Ser819, Phe820, Gly821, Arg825, Ala1131, Ser1132, Arg1135, Asp1138
Bithionol Met343, Phe346, Gly347, Ala350, Leu351, Val394, Gly395, Gly398, Ser399, Glu402,
Trp907, Gln948
Carvacrol Lys1002, Val1003, Val1004, Leu1006, Lys1007, Asp1008, Met1011
E1210 Ile802, Gln803, Ala804, Arg806, Ala807, Val810, Ala811, Gly812, Lys815, His933,
Ala938, Ser941, Asn942, Ser1132
Moxifloxacin Lys296, Arg1000, Leu1001, Lys1002, Gly1114, Phe1117, Thr1118, Pro1121
VT1129 Ile802, Gln803, Ala804, Arg806, Ala807, Val810, Ala811, Gly812, Glu813, Lys815
Table 16.
Analysis of interacting residues for Cryptococcus neoformans.
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• (Ile802, Gln803, Ala804, Arg806, Ala807, Val810, Ala811, Gly812, Glu813,
Lys815) are some recurring residues in Cryptococcus neoformans (Table 16).
• (Ala106, Leu107, Ser108, Ala109, Tyr112, Tyr322, Ile324, Phe390) and
(Tyr112, Gln116, Val117, Gly118, Gln119, Val120) are some recurring residues
in Staphylococcus aureus (Table 17).
6. Conclusion
The homology modeling was performed to determine the best template, from
which we concluded that 4m1m is preferred in Aspergillus fumigatus, Aspergillus
nidulans, Acinetobacter baumannii, and Candida albicans. In Cryptococcus neoformans
4f4c is preferred, and 3wme is preferred in Staphylococcus aureus.
The molecular docking led us to conclude that bithionol, levofloxacin, e1210,
tigecycline, and bithionol were the most efficient potential antibiotics for the
organisms Aspergillus fumigatus, Acinetobacter baumannii, Candida Albicans, Staph-
ylococcus aureus, and Cryptococcus neoformans, respectively. Each of the potential
antibiotics was found to be more effective than a number of the known antibiotics
in the treatment of that respective organism.
An analysis of the interacting residues showed us that:
• (Leu268, Lys273, Thr276, Asn279) and (Gly153, Val156, Arg157, Ser160) are
some recurring residues in Acinetobacter baumannii.
• (Phe942, Gly1058, Thr1059, Phe1061, Ser1062) and (Asn392, Leu938, Gly941)
are some recurring residues in Aspergillus fumigatus.
• (Phe1143, Thr1146, Phe1173, Asn1176, Tyr1177, Arg1179, Ile1180, Ile1317)
and (Gly978, His1357, Leu1358) are some recurring residues in Candida
albicans.
Antibiotics Interacting residues
Cephalexin Arg186, Thr302, Thr305, Gln306, Phe308, Ala309
Finafloxacin VAL178, Phe182, Ser247, Phe248, Ile251, Asn252, Gly292, Arg295, Arg296, Ala299
Vancomycin Pro172, Leu1776, Thr177, Tyr179, Val180, Phe181, Gly183, Arg184, Lys187
9346 Ala106, Leu107, Ser108, Ala109, Tyr112, Tyr322, Ile324, Phe390, Thr410, Arg414
Brilacidin Tyr94, Arg97, Lys98, Tyr101, Ile121, Val124, Ile425, Leu426, Phe427, Ser428, Glu473,
Arg474
Ceftobiprole Tyr112, Ala113, Asn115, Gln116, Val117, Gly118, Gln119, Val120, Ile121, Phe427
Gepotidacin Gln105, Ala106, Leu107, Ser108, Ala109, Tyr112, Ile324, Arg389, Phe390, Arg414,
Leu419
Moxifloxacin Tyr12, Trp87, Asn90, Lys91, Tyr94, Asp95, Lys98
Radezolid Arg97, Tyr101, Gln105, Tyr112, Gln116, Val117, Gly118, Gln11, Val120, Ile121, Val124,
Ile125
Tigecycline Gln105, Ala106, Leu107, Ser108, Ala109, Tyr322, Asp323, Ile324, Asn385, Arg389,
Phe390, Arg414, Gln421, Ile425
Table 17.
Analysis of interacting residues for Staphylococcus aureus.
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• (Ile802, Gln803, Ala804, Arg806, Ala807, Val810, Ala811, Gly812, Glu813,
Lys815) are some recurring residues in Cryptococcus neoformans.
• (Ala106, Leu107, Ser108, Ala109, Tyr112, Tyr322, Ile324, Phe390) and
(Tyr112, Gln116, Val117, Gly118, Gln119, Val120) are some recurring residues
in Staphylococcus aureus.
Appendix 1: FASTA sequences obatained from PSI – BLAST searches
>SST02482.1 lipid A export permease/ATP-binding protein MsbA [Acinetobacter
baumannii]
MIDKDLSTRQTFRRLWPTISPFKAGLFVAAIALVINAAGDAFMISLLKPLL-
DEGFEKADNDVLKWLPLAMLGLIIVRGASSFV-
STYCVSWVSGQVVMSMRRKLFGHMMGMPVSFFDQQSTGTLLSRITYDSEQ-
VAASSSGALITIIREGAYIIGLFAMMFYYSWQLSLILIVIAPIVSITIRIVSKRFR-
KISKNMQTGMGHVTASAEQMLKGHKEVLIFGGQKVE-
TERFNKVSNNMRSQSMKMVTASAISDPIIQLIASFALAFVLYAASFPEIREQLSPG-
TIAVVFSSMFALMRPLKSLTNVNSQFQRGMAACQTLFSILDTEQEK-
DEGTKVLSNVKGDIEFENVTFTYATKEHPALDDISFTLPAGKSVALVGRSGSGK-
STIANLITRFYDIDKGSIRIDGHDIREYTLESLRNQVALVSQHVYLFNDTIAN-
NIAYATDGRFSREQIEKAAEMAYAMDFIAKLDKGLDTVIGEN-
GVMLSGGQRQRIAIARALLRDAPILILDEATSALDTESERAIQAALDELQKNRTSL-
VIAHRLSTIENADEILVVQDGRIIERGNHKALLALEGAYAQLHKIQFSQ
>WP_051575420.1 ABC transporter ATP-binding protein [Staphylococcus aureus]
MKFKKFISYYRPYKRIFGLTLICSLLVTVITLVIPLIIRYITENLIQHFSVAHV-
KEIYLLGAAMVLLILIQFLCHIFIDYYGHVMGAKMEKDMSEELYE-
HIQSQPHHFFDRNSTGGLMSRLTGDLENLSELYHHGPEDILMYIIRFIGAVVIL-
LYINVELTIVMMLFIPIMIVVYWYYIKKLSSIYEQDKATNAEIHGFLENTIS-
GIKVTKSFTNESFESNQYKSLNKKAIEIKKKVHKYEALYNEIIGSIIQAMPVIIIVL-
GALLIMKKEISIGDLLAFVLYVGNIATPIEVLVKLSVQYNE-
GISGFNRFFKLMQLKPDITSENTHQQQSPHSNGAIQFDHVYFQYDQEYIIHNLNL-
TIEPGAYIAIVGPSGSGKSTIANLLPRFYDVTSGSITINHQDIRTIPLEELRQKI-
GIVQQDVYIFSSTVYENIKYGNPEASMDEIIHASKLANAHEFIQQLPNGYHTQI-
GEKGAKLSGGQKQRLSIARMFLKNPEVVILDEATSALDNLSEKVVQQ-
SLEQLTLNRTTIVIAHRLSTIRNADNIYVLTKEGIIESGNHDTLIEKQG-
FYYRMYINEEN
>KHC36224.1 alpha-factor-transporting ATPase [Candida albicans P76067]
MFQEKSEKSSFPKRSSSLRSPSDSPAITSKNVFMFVNYSKDWPLILVGILLMGG-
SAIATPMNTYIYGEIMGKLSQFYLQDQSNHSFSQDIVKLCVGLIGIGCCK-
MILVWLGMFTWLKFGEIQQSRARMQIYNKIINESQSWYDSKQNLIGQLTQINR-
CIEELRSCNGEILASLMQTIVLILALLIMSFYQSWSTTLIIMASFPIMALCG-
WYFGKLTYKAQQDENEVTSKASKVFNWCYVNPEMVRFFNSKNIELTKFKQ-
LIEKSAQFYYKLSHAVAANTAVLKTLTLMMFVQGFWFGNYLLSHNTI-
TINQLFTCFSSCLMLGQAVSGITELLAILNTGHAAADKISGFLLQPPS-
KAKLLLLHSKYPPFEIGSIYFKNVWFESNSQNSVAILQDVSFGILQNQFNF-
VIGKSGSGKSTIAKLLMRLYSVSRGTIEIDTVSIDKLDPKYICQNIILLEQNP-
VIFDDKTIAENIAIAIVDDYDSLQAIPYYLIEQSAHFALLSDLDLNMKVNQLTLSG
GQQQRISIARAYLKNSPVLIMDESFSALDTETKQCLIEKVKKWRIGKTTIFITHEY-
KNILDDENVIILDQGMIKNQGQFKKMKNEEIVQNYKSQGIETS-
SYETTSQSFSDNTKLPDGDYNYKTNPYILKDLESQIKEDTDNEKLMGVLAIL-
RYCSSTINGKSLLGFGILLAIFQGGSSPVFSYCFSKLLSTSLDSSIGLNSTQKILQWS-
CISLSIAIFTGVTSYLSEFILNYCGENWIVSLRQLTFFKLNNQDLSFFTRFDTNWSS-
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SEITALLMNDTRDLRNLISQFFPLLANLVSMTLIGIIWSIVSGWKLALV-
GISFVPLVLLVTVLYGKILESIENKYKCKVNNVELDLYRTITTIRTIKIFNIQQY-
FETVFKEDLKVLNSIGVYRALQTGIGFAISDLFSSIGQAIILFYGMKLISQFQY-
NYSQLLQVITLLSFTISNASILIHQLPEITRGQRAGTFIVKLLKDITST-
MEVNDSCGVSSVRKRNSKSGSDSIGTIGPVKDNQLFKKVTTDNDTLAISFNNVSF-
SYPNKLPYILQLKSISLDVKKFTTIGIVGQSGSGKSTILKILFRLYDIKISPDSNTTK-
KYHDQTVKIFNQNLYLINSGLLCQTIAIVPQFPKFFSGTIYDNLTYGINNTN-
SAGSNSSSSVSDSEIIKILKLVNLHQFIVSLPQGLLTIMNDSDNDNDNGNENENE-
NENGNTISTSSSTSFTFSGGQLQLLAIARALLRNPKILLLDECTSNLDPITTKIIIN-
VIKSLHGKLTILFVTHDKELMRIADNLIVMKDGQIVEQGDFQQLISND-
GEFTKITKTII
>OWZ59602.1 ATP-binding cassette, subfamily B (MDR/TAP), member 1
[Cryptococcus neoformans var. grubii c45]
MSASPGLTAAAAGPDHLQARRDEKVIDSEKDALAHDAHAVNSGIPYPTA-
TAPNVGAPTVPIIVGRVSSAPEGKISRSSIAASSDTLRNSPLEKPISNAVSKSH-
PYKKSKFDFLKSRKKKEEEERKNKEKEKEASVLPPVSFFALFRFAA-
PLEIIAMVLGLVLAVAAGSCQPLMTLIFGRLTTSFTNYAVIANQISQGGLTPET-
SAALQAAKDDLKTQSGHNALYLMAIGIGMFLATWLYMFIWNVTGELNSKRIR-
ERYLAAVLRQEIAYFDDLGAGEVATRIQTDCHLVQEGTSEKVALVF-
QYAGTFVCGFVLAFVRSPRLAGALVSILPVIMLCGGIMMTAMAKFGTAALDHIA-
KAGSLAEEVIGSIRTVQAFGKEKILGDKFADHIEQSKIVGRKGSIFEGFGLSIMFF-
VIYAAYALAFFYGGILVSNGQADSGIVINVFMSILIGSFSMAMLAPELAAVTKAR-
GAAAKLFATIDRVPAIDSASEEGFKPDGLRGEISFENVKFHYPSRPSIPILKGFTTT-
FEAGKTFALVGASGSGKSTVVSLIERFYDPVSGVVKLDGRDIRSLNLNWLRQ-
QIGLVSQEPTLFGTTVRGNVEHGLIGSRYENASLEEKFELVKKACVDANAHN-
FIMKLPQGYDTMVGERGMLLSGGQKQRVAIARAIVSDPRILLLDEATSALDTQ-
SEGIVQDALDKASRGRTTITIAHRLSTIRDADRIYVMGGGEVLEQGSHNDLLA-
NENGPYAQLVNNQKLAQEAAAEALQVDDDIDDLDDAVFIGGSSPM-
QEKDKQLHRAVTGRSLASIAMDDIQAKRAEEVAGEDKIPSSFGLYARLLKMN-
SADKFIYILAFIAAICAGMVYPSLAILFGKALSDFEIQDPAELRHALSRSALWYFI-
TALAAAFVIFFQSAGFSRAGWDLNGVLRKKLFTATLRHDIEWFDEERNST-
GAVTSNLADQPQKVQGLFGPTLGTVVQSCATLIGGCIIGLCYGPLLALIGIACI-
PILVSGGYIRLKVVVLKDQRMKKLHAASAHLASEAAGAVKTVASLTREKDVR-
RIYSEALKAPMKLNFRTSIKSQCLFAASQGLTFCIIALVFYIGALWIIDGKYSTAS-
FYTVLNSIVFASIQAGNVFTFVPDASKANSSAASIFRSIDNEPAINAES-
NEGKVLDHKHVVGHVRIEGVHFRYPTRPGVRVLRNLTIDVPAGTY-
VALVGPSGCGKSTTIQMLERFYDPLAGRVTLDGIDIKELNLASYRSQISLVSQEP-
TLYAGTIRFNILLGANKPIEEVTQDEIDAACKDANIYDFIVSLPDGFD-
TEVGGKGSQLSGGQKQRIAIARALIRNPKVLLLDEATSALDSQSEKVVQEALD-
KAAKGRTTIAIAHRLSSIQHSDRIYYFSEGRVAEHGTHQELLAKKG-
GYYELVQMQNLSRQ
>KEY77376.1 ABC multidrug transporter Mdr1 [Aspergillus fumigatus var.
RP-2014]
MPAPETGASSREKSLEDLQVATLEKGRSTSSFGADNEKPHDHHSLSDTI-
MAPPDGKKKDHGKAVDLNDDSLFAHLQEHEKEVLKRQLDAPSVKVSFFTLYR-
YASRKDILIILVSAICAIAAGAALPLFTILFGSLASAFQGISLGTMPYHE-
FYHKLTKNVLYFVYLGIAEFVTVYVSTVGFIYTGEHLTQKIRENYLEAILRQN-
MAYFDKLGAGEVTTRITADTNLIQDAISEKVGLTLTAFATFVTAFIVAYVKYWK-
LALICTSTIVALVMVMGGGSRFIVKYSKKSIESYGAGGTVAEEVISSIRNA-
TAFGTQDKLAKQYETHLAEAEKWGVKQQVILGMMIGGMFGIMFS-
NYGLGFWMGSRFVVGKEVNVGQVLTVLMSILIGSFSLGNVAPNGQAFTNG-
VAAAAKIYSTIDRRSPLDPYSDEGKVLDHFEGNIEFRNVKHIYPSRPEVTV-
MEDVSLSMPAGKTTALVGPSGSGKSTVVGLVERFYLPVGGQVLLDGH-
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DIQTLNLRWLRQQISLVSQEPVLFSTTIFRNIEHGLIGTKFEHESKDKIRELVE-
NAARMANAHDFIMALPEGYDTNVGQRGFLLSGGQKQRIAIARAIVSDPKILLL-
DEATSALDTKSEGVVQAALDKAAEGRTTIVIAHRLSTIKTAHNIVAMVGG-
KIAEQGTHDELVDRKGTYYKLVEAQRINEEKEAEALEADADMDADDFGQEGV-
TRIKTAVSSSNSLDAVDEKARLEMKRTGTQKSVSSAVLSKKVPEQFE-
KYSLWTLVKFIGAFNRPELGYMLIGLTFSFLAGGGQPTQAFLYAKAISTLSL-
PESMFHKLRHDANFWSLMFFVVGIAQFISLSINGTAFAICSERLIRRARSQAFR-
SILRQDISFFDREENSTGALTSFLSTETKNLSGVSGVTLGTIIMTSTTLGAAMIIA-
LAIGWKLALVCISVVPILLACGFLRFYMLAQFQQRSKSAYEGSASYACEATSAIRT-
VASLTREQDVWGVYHDQLQKQGRKSLISVLRSSLLYASSQALVFFCVALGF-
WYGGTLLGHHEYSIFRFFVCFSEILFGAQSAGTVFSFAPDMGKA-
KNAAAQFKKLFDSKPTIDIWSDEGEKLESMEGEIEFRDVHFRYPTR-
PEQPVLRGLNLSVKPGQYIALVGPSGCGKSTTIALLERFYDALAGGVFVDGK-
DITKLNVNSYRSFLSLVSQEPTLYQGTIKENILLGVDKDDVSEETLIKVCKDA-
NIYDFVMSLPEGFDTVVGSKGGMLSGGQKQRVAIARALLRDPKVLLLDEAT-
SALDSESEKVVQAALDAAARGRTTIAVAHRLSTIQNADIIYVFDQGKIVESGTH-
HELIRNKGRYYELVNLQSLGKTH
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